AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38896056 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence in situ hybridization studies
Number of subjects: 7285
Study 38896056 — intervention group
Group type: EXPERIMENTAL
Intervention: Performing genetic studies
Number of subjects: 7285
Study 38896141 — intervention group
Group type: EXPERIMENTAL
Intervention: fSCIG 10% with conventional ramp-up at 1.0 g/kg/infusion
Number of subjects: 51
Study 38896141 — intervention group
Group type: COMPARATOR
Intervention: fSCIG 10% with no ramp-up at 1.0 g/kg/infusion
Number of subjects: 51
Study 38896141 — intervention group
Group type: EXPERIMENTAL
Intervention: fSCIG 10% with accelerated ramp-up at 1.0 g/kg/infusion
Number of subjects: 51
Study 38896141 — intervention group
Group type: EXPERIMENTAL
Intervention: fSCIG 10% with conventional ramp-up at 0.4 g/kg/infusion
Number of subjects: 51
Study 38896141 — intervention group
Group type: EXPERIMENTAL
Intervention: fSCIG 10% (all arms)
Number of subjects: 51
Study 38896199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 15 mg twice daily (after uptitration from 5 mg twice daily for the first week)
Number of subjects: 393
Study 38896199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin
Number of subjects: 393
Study 38896199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 393
Study 38896211 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (CT) program (30 sessions, 90 min each)
Number of subjects: 226
Study 38896211 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine activities)
Number of subjects: 226
Study 38896223 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactiplantibacillus plantarum HEAL9 (LpHEAL9)
Number of subjects: 66
Study 38896223 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactiplantibacillus plantarum HEAL9 + Berries
Number of subjects: 66
Study 38896223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 38896223 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactiplantibacillus plantarum HEAL9 (LpHEAL9) and LpHEAL9 + Berries
Number of subjects: 66
Study 38896229 — intervention group
Group type: EXPERIMENTAL
Intervention: vWF-Ag
Number of subjects: 72
Study 38896229 — intervention group
Group type: COMPARATOR
Intervention: Indocyanine green clearance
Number of subjects: 72
Study 38896229 — intervention group
Group type: COMPARATOR
Intervention: Computation of future liver remnant
Number of subjects: 72
Study 38896264 — intervention group
Group type: EXPERIMENTAL
Intervention: Alglucosidase alfa treatment for ≤13 years
Number of subjects: 485
Study 38896381 — intervention group
Group type: EXPERIMENTAL
Intervention: apremilast 30 mg twice daily
Number of subjects: 0
Study 38896381 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 38896380 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg/day
Number of subjects: 453
Study 38896380 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg (dose increase from 100 mg)
Number of subjects: 453
Study 38896403 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonidegib
Number of subjects: 0
Study 38896403 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib
Number of subjects: 0
Study 38896403 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol modifications (treatment interruptions and dose reductions)
Number of subjects: 0
Study 38896403 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic and pharmacologic interventions
Number of subjects: 0
Study 38896452 — intervention group
Group type: EXPERIMENTAL
Intervention: webMFT
Number of subjects: 56
Study 38896452 — intervention group
Group type: COMPARATOR
Intervention: MVPA tracking (control)
Number of subjects: 56
Study 38896602 — intervention group
Group type: EXPERIMENTAL
Intervention: Delgocitinib ointment
Number of subjects: 11
Study 38896602 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical JAK inhibition
Number of subjects: 11
Study 38896602 — intervention group
Group type: COMPARATOR
Intervention: Afatinib (EGFR inhibitor)
Number of subjects: 11
Study 38896810 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-QuIC seeding activity in CSF
Number of subjects: 41
Study 38896810 — intervention group
Group type: COMPARATOR
Intervention: RT-QuIC negative
Number of subjects: 41
Study 38896810 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodegenerative and neuroinflammatory markers
Number of subjects: 41
Study 38896810 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF PrP levels
Number of subjects: 41
Study 38896810 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF prion seeding activity
Number of subjects: 41
Study 38896810 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronal damage and neuroinflammation markers
Number of subjects: 41
Study 38896837 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Aid-Package (mHealth intervention)
Number of subjects: 439
Study 38896837 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 439
Study 38896851 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 586
Study 38896851 — intervention group
Group type: COMPARATOR
Intervention: Usual obesity care
Number of subjects: 586
Study 38896853 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning computed risk score (DLCR) model
Number of subjects: 707
Study 38896853 — intervention group
Group type: COMPARATOR
Intervention: UISS/Leibovich score/Rad-Score
Number of subjects: 707
Study 38897097 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nomegestrol acetate/estradiol 1.5 mg/2.5 mg/day for 14 days (random start)
Number of subjects: 80
Study 38897097 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pharmaceutical treatment)
Number of subjects: 80
Study 38897103 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-foot exercises program (3 sessions a day, 3 days a week for 8 weeks)
Number of subjects: 39
Study 38897103 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine treatment and care)
Number of subjects: 39
Study 38897136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 325
Study 38897155 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments (248 treatments administered)
Number of subjects: 120
Study 38897155 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age at disease onset
Number of subjects: 120
Study 38897155 — intervention group
Group type: EXPERIMENTAL
Intervention: Short delay from onset of relapse to treatment initiation
Number of subjects: 120
Study 38897584 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hyperthermia with MR-guided high intensity focused ultrasound (MR-HIFU) combined with concurrent chemoradiation (30.6 Gy in 1.8 Gy fractions with capecitabine)
Number of subjects: 6
Study 38897621 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete ANS exposure
Number of subjects: 725
Study 38897621 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial ANS exposure
Number of subjects: 725
Study 38897621 — intervention group
Group type: COMPARATOR
Intervention: No ANS exposure
Number of subjects: 725
Study 38897621 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial and complete ANS exposure
Number of subjects: 725
Study 38898018 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg on day 1 plus modified TPF (docetaxel 75 mg/m2) for three cycles
Number of subjects: 0
Study 38898018 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus modified TPF
Number of subjects: 0
Study 38898120 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrectinib 600 mg daily
Number of subjects: 55
Study 38898120 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrectinib (integrated analysis)
Number of subjects: 55
Study 38898468 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint athletes
Number of subjects: 24
Study 38898468 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance athletes
Number of subjects: 24
Study 38898522 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS)
Number of subjects: 42
Study 38898522 — intervention group
Group type: COMPARATOR
Intervention: Sham-taVNS
Number of subjects: 42
Study 38898537 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Intervention for Trauma in Schools (CBITS)
Number of subjects: 90
Study 38898537 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment-as-usual condition (TAU +)
Number of subjects: 90
Study 38898573 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac shockwave therapy (SWT)
Number of subjects: 63
Study 38898573 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 63
Study 38898664 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional impairment (defined as MNA-SF ≤11)
Number of subjects: 541
Study 38898664 — intervention group
Group type: EXPERIMENTAL
Intervention: MNA-SF ≤11
Number of subjects: 541
Study 38898892 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal aptitudes and personality traits
Number of subjects: 156
Study 38898892 — intervention group
Group type: EXPERIMENTAL
Intervention: Social determinants of health and interpersonal relationships
Number of subjects: 156
Study 38898892 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological capacity, physical capacity, physical opportunity, social opportunity, reflective motivation, automatic motivation
Number of subjects: 156
Study 38898892 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for control, overthinking, ambivalence
Number of subjects: 156
Study 38899114 — intervention group
Group type: EXPERIMENTAL
Intervention: da Vinci SP system for anatomical lung resection
Number of subjects: 35
Study 38899206 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of interleukin-33 (IL-33) signaling
Number of subjects: 0
Study 38899206 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking the IL-33 pathway
Number of subjects: 0
Study 38899545 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD)
Number of subjects: 5752
Study 38899545 — intervention group
Group type: COMPARATOR
Intervention: Haemodialysis (HD)
Number of subjects: 5752
Study 38899599 — intervention group
Group type: EXPERIMENTAL
Intervention: Steps 1-2 (non-surgical) of periodontal therapy (test group; n=37)
Number of subjects: 74
Study 38899599 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group; n=37)
Number of subjects: 74
Study 38899693 — intervention group
Group type: EXPERIMENTAL
Intervention: ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) administered every 21 days for six cycles
Number of subjects: 60
Study 38899693 — intervention group
Group type: EXPERIMENTAL
Intervention: ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide)
Number of subjects: 60
Study 38899695 — intervention group
Group type: EXPERIMENTAL
Intervention: CM313 (anti-CD38 monoclonal antibody) administered intravenously at a dose of 16 mg/kg every week for 8 weeks
Number of subjects: 22
Study 38899695 — intervention group
Group type: EXPERIMENTAL
Intervention: CM313 (anti-CD38 monoclonal antibody)
Number of subjects: 22
Study 38899716 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus Trametinib
Number of subjects: 870
Study 38899716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 870
Study 38899776 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified delivery group (on-demand exercise videos and weekly exercise duration leaderboards)
Number of subjects: 40
Study 38899776 — intervention group
Group type: COMPARATOR
Intervention: Packet group (take-home packet)
Number of subjects: 40
Study 38899824 — intervention group
Group type: EXPERIMENTAL
Intervention: Tub bathing (experimental group)
Number of subjects: 0
Study 38899824 — intervention group
Group type: COMPARATOR
Intervention: No tub bathing (control group)
Number of subjects: 0
Study 38899824 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnel-experimental group (tub bathing with tunnel phototherapy)
Number of subjects: 0
Study 38899824 — intervention group
Group type: COMPARATOR
Intervention: Tunnel control group (no tub bathing with tunnel phototherapy)
Number of subjects: 0
Study 38899824 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-emitting diode-experimental group (tub bathing with LED phototherapy)
Number of subjects: 0
Study 38899824 — intervention group
Group type: COMPARATOR
Intervention: Light-emitting diode control group (no tub bathing with LED phototherapy)
Number of subjects: 0
Study 38900037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib in combination with R-GemOx (rituximab, gemcitabine, and oxaliplatin)
Number of subjects: 64
Study 38900037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib maintenance
Number of subjects: 64
Study 38900037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib in combination with R-GemOx
Number of subjects: 64
Study 38900037 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 64
Study 38900182 — intervention group
Group type: EXPERIMENTAL
Intervention: Resiliency education
Number of subjects: 903
Study 38900182 — intervention group
Group type: EXPERIMENTAL
Intervention: Cautionary education
Number of subjects: 903
Study 38900182 — intervention group
Group type: COMPARATOR
Intervention: Control group (standardized Army deadlift education only)
Number of subjects: 903
Study 38900225 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP + 4
Number of subjects: 46
Study 38900225 — intervention group
Group type: COMPARATOR
Intervention: Sham-CPAP (Control)
Number of subjects: 46
Study 38900283 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised qualitative assessment
Number of subjects: 140
Study 38900283 — intervention group
Group type: EXPERIMENTAL
Intervention: GWR-8
Number of subjects: 140
Study 38900283 — intervention group
Group type: EXPERIMENTAL
Intervention: GWR-4
Number of subjects: 140
Study 38900283 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated GWR
Number of subjects: 140
Study 38900305 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recovery programs (ERP)
Number of subjects: 50
Study 38900416 — intervention group
Group type: EXPERIMENTAL
Intervention: FCH PET/CT (FCH1)
Number of subjects: 57
Study 38900416 — intervention group
Group type: COMPARATOR
Intervention: MIBI SPECT/CT (MIBI1)
Number of subjects: 57
Study 38900426 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable gardening intervention
Number of subjects: 381
Study 38900426 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted control
Number of subjects: 381
Study 38900435 — intervention group
Group type: EXPERIMENTAL
Intervention: SOR-TACE (sorafenib 400 mg twice daily plus on-demand TACE)
Number of subjects: 162
Study 38900435 — intervention group
Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 162
Study 38900435 — intervention group
Group type: EXPERIMENTAL
Intervention: SOR-TACE
Number of subjects: 162
Study 38900452 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX (6 cycles preoperative and 6 cycles adjuvant)
Number of subjects: 46
Study 38900484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreous lampalizumab, 0.1 mL, every 4 weeks
Number of subjects: 1851
Study 38900484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreous lampalizumab, 0.1 mL, every 6 weeks
Number of subjects: 1851
Study 38900484 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure every 4 weeks
Number of subjects: 1851
Study 38900484 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure every 6 weeks
Number of subjects: 1851
Study 38900490 — intervention group
Group type: EXPERIMENTAL
Intervention: CRDS cases
Number of subjects: 68
Study 38900490 — intervention group
Group type: COMPARATOR
Intervention: Control patients with suspected supraventricular tachycardia
Number of subjects: 68
Study 38900490 — intervention group
Group type: COMPARATOR
Intervention: Control patients (UCA and CPVT)
Number of subjects: 68
Study 38900505 — intervention group
Group type: EXPERIMENTAL
Intervention: Polar H10 chest monitor
Number of subjects: 14
Study 38900505 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit Inspire HR
Number of subjects: 14
Study 38900513 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline active coping
Number of subjects: 115
Study 38900565 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic stress exposure (including stress from COVID-19)
Number of subjects: 359
Study 38900565 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-child relationship quality, caregiver education, and caregiver self-regulation
Number of subjects: 359
Study 38900565 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote data collection methods including questionnaires and measures
Number of subjects: 359
Study 38900570 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological distress in caregivers (measured by various instruments)
Number of subjects: 51
Study 38900570 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal ALS patients
Number of subjects: 51
Study 38900570 — intervention group
Group type: EXPERIMENTAL
Intervention: Male ALS patients with preserved cognition
Number of subjects: 51
Study 38900700 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated diabetes management game
Number of subjects: 48
Study 38900700 — intervention group
Group type: COMPARATOR
Intervention: Control group playing the game alone
Number of subjects: 48
Study 38900773 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented high zinc agronomically biofortified wheat flour flatbread
Number of subjects: 1000
Study 38900773 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfermented high zinc agronomically biofortified wheat flour flatbread
Number of subjects: 1000
Study 38900773 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-harvest zinc-fortified wheat flour flatbread
Number of subjects: 1000
Study 38900773 — intervention group
Group type: COMPARATOR
Intervention: Low zinc conventional whole wheat flour flatbread
Number of subjects: 1000
Study 38900773 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (fermented, unfermented, post-harvest zinc-fortified)
Number of subjects: 1000
Study 38900984 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR-A1811 (1.0 to 8.0 mg/kg, IV, once every 3 weeks)
Number of subjects: 307
Study 38900987 — intervention group
Group type: EXPERIMENTAL
Intervention: Fianlimab 1,600 mg and cemiplimab 350 mg intravenously once every 3 weeks for up to 51 weeks (with optional additional 51 weeks if clinically indicated)
Number of subjects: 118
Study 38901008 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine, mean dose at week 145: 40.4 mg/d for psychotic disorders, 38.5 mg/d for mood and other disorders, 39.9 mg/d for those receiving DRAs, 38.5 mg/d for those not receiving DRAs.
Number of subjects: 343
Study 38901008 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine
Number of subjects: 343
Study 38901021 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive risk models (PRMs) for CRS
Number of subjects: 54
Study 38901084 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (n = 43)
Number of subjects: 88
Study 38901084 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day Letrozole (n = 24)
Number of subjects: 88
Study 38901084 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day Letrozole (n = 21)
Number of subjects: 88
Study 38901179 — intervention group
Group type: EXPERIMENTAL
Intervention: KEβHB-supplemented beverage
Number of subjects: 18
Study 38901179 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 18
Study 38901293 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous drain insertion
Number of subjects: 162
Study 38901293 — intervention group
Group type: COMPARATOR
Intervention: Control (no subcutaneous drain)
Number of subjects: 162
Study 38901299 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference-based participation in orthopaedic care
Number of subjects: 458
Study 38901299 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocal communication, opportunities for partaking in planning, and learning how to manage symptoms/issues
Number of subjects: 458
Study 38901299 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip fracture surgery
Number of subjects: 458
Study 38901423 — intervention group
Group type: EXPERIMENTAL
Intervention: 5:2 intermittent fasting
Number of subjects: 40
Study 38901423 — intervention group
Group type: COMPARATOR
Intervention: Healthy living diet
Number of subjects: 40
Study 38901425 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI+BEV
Number of subjects: 103
Study 38901425 — intervention group
Group type: COMPARATOR
Intervention: CAPOXIRI+BEV
Number of subjects: 103
Study 38901444 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide
Number of subjects: 124
Study 38901489 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided deep sedation (BIS range, 40-60)
Number of subjects: 99
Study 38901489 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment (CA)
Number of subjects: 99
Study 38901559 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin regulation in men with NASH
Number of subjects: 17
Study 38901559 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin regulation in men with simple steatosis
Number of subjects: 17
Study 38901633 — intervention group
Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel)
Number of subjects: 127
Study 38901633 — intervention group
Group type: COMPARATOR
Intervention: Mosunetuzumab
Number of subjects: 127
Study 38901636 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 156
Study 38901636 — intervention group
Group type: COMPARATOR
Intervention: BPI
Number of subjects: 156
Study 38901823 — intervention group
Group type: EXPERIMENTAL
Intervention: Cantilevered zirconia RBFPDs
Number of subjects: 36
Study 38901858 — intervention group
Group type: EXPERIMENTAL
Intervention: JADE-PRISM group (multicomponent care model with specialist-led team-based management)
Number of subjects: 884
Study 38901858 — intervention group
Group type: COMPARATOR
Intervention: Usual care (JADE-only)
Number of subjects: 884
Study 38901877 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients with asthma
Number of subjects: 773
Study 38901877 — intervention group
Group type: COMPARATOR
Intervention: Male patients with asthma
Number of subjects: 773
Study 38901942 — intervention group
Group type: EXPERIMENTAL
Intervention: Family caregivers' nutritional status
Number of subjects: 120
Study 38901942 — intervention group
Group type: EXPERIMENTAL
Intervention: CRs' MNA scores
Number of subjects: 120